FEZOLINETANT (Veoza®)

Clinical Indication

for treating moderate to severe vasomotor symptoms associated with menopause

Comments

Usually recommended and initiated by secondary care specialists. However, primary care clinicians with a specialist interest, appropriate experience, and competency in menopause management may initiate treatment.

In line with NICE TA1143

Funding from: 29th June 2026.

 

Date of classification

June 2026

Yellow

Specialist recommendation: Medicines initiated (and stabilised where appropriate) or recommended by a specialist service for prescribing in primary care. Requests should be clearly communicated either through written communication including using approved paperwork if available or verbal means as appropriate .